News
Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...
TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy ...
Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...
Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...
3don MSN
On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.
6d
Barchart on MSNEli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...
Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...
Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results